

Expansion of Clinical Trials to the Moffitt Ambulatory Centers

Allison Richards, Matthew Ott, Erica Royster, Tiffany Freeman, Marjorie Colon Colon, Maria Grullon, Michelle Burton, Elyse Cadena, Claribel Michel, Pelumi Olaore, Emilie Fussell, Milijana Ugrenovic-Petrovic, Hatem Soliman, Jay Lebsack



Background

Moffitt Cancer Center is focused on growing services through the introduction of Moffitt Ambulatory Centers (MACs), designed to expand our network of ambulatory clinics across the Tampa Bay area. The Clinical Trials Office (CTO) has brought the expansion of clinical trial opportunities to the forefront of this mission. It is important to develop and stabilize a priority pathway for identifying and activating trials that continue to offer hope with more convenience and accessibility to patients.

Goals

- Maximizing access to clinical trials closer to home, achieved by:
- Enhancing clinical trial portfolio performance through investigator engagement, feasibility assessment and workflow optimization
 - Developing site management plans and clinical trial prioritization
 - Supporting study team growth, cross-training and multi-specialty collaboration
 - Clinical research integration, education, and adaptability into clinical pathways
 - Maximizing prescreening efforts and upscaling research-related clinical encounters
 - Providing optimal patient care, offering flexibility in scheduling, per patient preference

Solutions and Methods

- We developed a 3-phase approach consisting of
- protocol assessment and feasibility review,
 - operational review, and
 - a trial implementation checklist showing trial selection and priority pathway as standardized mapping tool that illustrates how trials can be operationalized.

How Do We Open Studies at the MACs?



MACs Clinical Trial Activity ^o	FY20	FY21	FY22	FY23	FY24	FY25 YTD
Clinical Trials Open for Treatment at Any MAC	N/A	N/A	3	2	9	12
Patients Referred/Consented by MAC MD Resulting in an Accrual/Enrollment	N/A	N/A	3	1	22	60
Unique MAC MDs with a Referral/Consent	N/A	0.8%	1.3%	1.2%	1.2%	1.5%
Clinical Trial Treatment That Occurred at a MAC	N/A	N/A	N/A	N/A	5	81
Clinical Trial Related Encounters Occurring at a MAC	N/A	N/A	26*	4*	35	150

^oData reflects through April 2025
^{*}Treatment total reflects a single study
^{*}No MAC staffing through FY23 due to turnover/hiring freeze

Outcomes

- Expansion of clinical trials requires additional clinical trial resources that better help the CTO align process workflows with MAC clinical operations, allowing the CTO to analyze and further optimize best practices that promote patient care satisfaction and understanding of their clinical trial participation.
- Creation of resources: Site Management Plan, Clinical Trials Dashboards, Referral Tools, Work Instructions, Procedures Matrix, Trial Priority Table/Score
 - 274+ clinical trial protocol assessments conducted
 - Standardized integration plan of clinical trial workflows into future MAC locations
 - Increased clinical trial activity with 12 treatment trials opened, 60 patients referred and enrolled resulting in a 60% increase in number of trial treatments occurring at a MAC, with 1.5% of research-related clinical encounters occurring at a MAC

Refinements, Questions, and Next Steps

- Initially, only clinical trials that were already open at primary locations were operationalized at the MACs.
- We learned there is greater efficiency in evaluating the suitability of a trial during the site activation process.
 - We gained insight in understanding patient populations seen at the MAC locations through investigator engagement and development of clinical trial provider champions, which we anticipate will increase clinical trial opportunities, activity and accruals.
 - To understand effectiveness and productivity, we will introduce assessment of clinical trial activity at 90-day intervals.